成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

  2. Anti-infection
  3. HCV
  4. Sofosbuvir

Sofosbuvir  (Synonyms: 索非布韋; GS-7977; PSI-7977)

目錄號: HY-15005 純度: 99.97%
COA 產(chǎn)品使用指南 技術(shù)支持

Sofosbuvir (GS-7977) 是 HCV RNA復(fù)制抑制劑，EC50 為 92 nM。

MCE 的所有產(chǎn)品僅用作科學(xué)研究或藥證申報(bào)，我們不為任何個(gè)人用途提供產(chǎn)品和服務(wù)

Sofosbuvir Chemical Structure

Sofosbuvir Chemical Structure

CAS No. : 1190307-88-0

1.  客戶無需承擔(dān)相應(yīng)的運(yùn)輸費(fèi)用。

2.  同一機(jī)構(gòu)（單位）同一產(chǎn)品試用裝僅限申領(lǐng)一次，同一機(jī)構(gòu)（單位）一年內(nèi)

     可免費(fèi)申領(lǐng)三個(gè)不同產(chǎn)品的試用裝。

3.  試用裝只面向終端客戶。

規(guī)格 價(jià)格 是否有貨 數(shù)量
10 mM * 1 mL in DMSO ￥431
In-stock
1 mg ￥185
In-stock
5 mg ￥370
In-stock
10 mg ￥500
In-stock
50 mg ￥640
In-stock
100 mg ￥770
In-stock
500 mg ￥1100
In-stock
1 g ￥1400
In-stock
5 g   詢價(jià)  
10 g   詢價(jià)  

* Please select Quantity before adding items.

Customer Review

Other Forms of Sofosbuvir:

MCE 顧客使用本產(chǎn)品發(fā)表的 104 篇科研文獻(xiàn)

WB

    Sofosbuvir purchased from MCE. Usage Cited in: Eur J Med Chem. 2018 Jan 1;143:1053-1065.  [Abstract]

    GS4.3 cells are treated with 7f (20 μM), or Telaprevir (0.5μM), Sofosbuvir (0.8 μM), Daclatasvir (0.15 μM) or solvent control for 6 days.

    Sofosbuvir purchased from MCE. Usage Cited in: Eur J Med Chem. 2018 Jan 1;143:1053-1065.  [Abstract]

    Huh7.5 cells are infected with HCV and simultaneously treated with 7f (10 μM) or DAA (0.04 μM Simeprevir, 0.08 μM Sofosbuvir, or 16 pM Daclatasvir) or 7f plus DAA.

    Sofosbuvir purchased from MCE. Usage Cited in: Biomed Res Int. 2017;2017:1236801.  [Abstract]

    Huh7.5 (HCV+) cells are treated with 1 μM of Sofosbuvir or solvent control. At 24 hours, the cells are washed and continuously incubated with fresh culture media containing drugs again for 48 hours. The cultural supernatants are then harvested and directly incubated to na?ve Huh7.5 cells. After been passaged 1~3 times, the newly infected cells are treated with 1 μM of Sofosbuvir for 72 hours. Intracellular proteins are extracted and detected with WB.

    Sofosbuvir purchased from MCE. Usage Cited in: J Med Chem. 2016 Nov 23;59(22):10268-10284.  [Abstract]

    Huh7.5 cells are infected with HCV (45 IU/cell) and simultaneously treated with Simeprevir (A, 0.025 μM), Sofosbuvir (B, 0.1 μM), or Daclatasvir (C, 16 pM) alone or with 1 (6.25 μM).

    • 生物活性

    • 實(shí)驗(yàn)參考方法

    • 純度 & 產(chǎn)品資料

    • 參考文獻(xiàn)

    生物活性

    Sofosbuvir (GS-7977) is an HCV RNA replication inhibitor with an EC50 of 92 nM[1].

    IC50 & Target

    EC50: 92±5 nM (HCV)[1]
    細(xì)胞效力
    (Cellular Effect)
    Cell Line Type Value Description References
    Cardiac muscle cell CC50
    > 300 μM
    Compound: SOF
    Cardiotoxicity against human embryonic stem cell-induced ventricular cardiomyocytes administered on day 7 and measured on day 10 after 30 mins incubation by CellTiter Glo assay
    Cardiotoxicity against human embryonic stem cell-induced ventricular cardiomyocytes administered on day 7 and measured on day 10 after 30 mins incubation by CellTiter Glo assay
    		[PMID: 30653317]
    CCRF-CEM CC50
    > 100 μM
    Compound: SOF
    Cytotoxicity against human CCRF-CEM assessed reduction in cell viability after 4 days by MTT assay
    Cytotoxicity against human CCRF-CEM assessed reduction in cell viability after 4 days by MTT assay
    		[PMID: 30653317]
    CCRF-CEM CC50
    > 100 μM
    Compound: 1; SOF
    Cytotoxicity against human CEM cells assessed as inhibition of cell proliferation after 4 days by MTT assay
    Cytotoxicity against human CEM cells assessed as inhibition of cell proliferation after 4 days by MTT assay
    		[PMID: 28595015]
    CCRF-CEM CC50
    > 100 μM
    Compound: Sofosbuvir
    Cytotoxicity against human CEM cells assessed as reduction in cell viability after 6 days by trypan blue exclusion assay
    Cytotoxicity against human CEM cells assessed as reduction in cell viability after 6 days by trypan blue exclusion assay
    		[PMID: 29066308]
    CCRF-CEM CC50
    > 100 μM
    Compound: SOF; 1
    Cytotoxicity against human CEM cells after 6 days by trypan blue exclusion method
    Cytotoxicity against human CEM cells after 6 days by trypan blue exclusion method
    		[PMID: 30655167]
    HepaRG CC50
    44 μM
    Compound: SOF
    Cytotoxicity in human HepaRG cells assessed as reduction in cell viability incubated for 14 days by CellTiter-Glo assay
    Cytotoxicity in human HepaRG cells assessed as reduction in cell viability incubated for 14 days by CellTiter-Glo assay
    		[PMID: 30653317]
    Hepatocyte CC50
    > 300 μM
    Compound: SOF
    Cytotoxicity against human primary hepatocytes assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human primary hepatocytes assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 30653317]
    HepG2 CC50
    > 50 μM
    Compound: Sofosbuvir
    Cytotoxicity against human HepG2 cells after 96 hrs by CCK-8 assay
    Cytotoxicity against human HepG2 cells after 96 hrs by CCK-8 assay
    		[PMID: 29801997]
    HepG2 IC50
    > 50 μM
    Compound: 1; SOF
    Mitochondrial toxicity in human HepG2 cells assessed as inhibition of cytochrome c oxidase subunit 2 DNA levels measured on day 14 by RT-PCR method
    Mitochondrial toxicity in human HepG2 cells assessed as inhibition of cytochrome c oxidase subunit 2 DNA levels measured on day 14 by RT-PCR method
    		[PMID: 28595015]
    HepG2 IC50
    > 50 μM
    Compound: 1; SOF
    Cytotoxicity against human HepG2 cells assessed as inhibition of nuclear DNA levels measured on day 14 by RT-PCR method
    Cytotoxicity against human HepG2 cells assessed as inhibition of nuclear DNA levels measured on day 14 by RT-PCR method
    		[PMID: 28595015]
    HepG2 IC50
    > 50 μM
    Compound: SOF
    Mitochondrial toxicity in human HepG2 cells assessed as inhibition of cytochrome c oxidase subunit 2 DNA level followed by medium plus drugs replenishment every 3 to 4 days for 14 days relative to control
    Mitochondrial toxicity in human HepG2 cells assessed as inhibition of cytochrome c oxidase subunit 2 DNA level followed by medium plus drugs replenishment every 3 to 4 days for 14 days relative to control
    		[PMID: 30653317]
    HepG2 IC50
    45 μM
    Compound: SOF
    Mitochondrial toxicity in human HepG2 cells assessed as inhibition of nuclear ribosomal-DNA level followed by medium plus drugs replenishment every 3 to 4 days for 14 days relative to control
    Mitochondrial toxicity in human HepG2 cells assessed as inhibition of nuclear ribosomal-DNA level followed by medium plus drugs replenishment every 3 to 4 days for 14 days relative to control
    		[PMID: 30653317]
    HK-2 CC50
    > 300 μM
    Compound: SOF
    Nephrotoxicity in human HK2 cells after 72 hrs by Hoechst 33342/HCS live/dead green dye-based assay
    Nephrotoxicity in human HK2 cells after 72 hrs by Hoechst 33342/HCS live/dead green dye-based assay
    		[PMID: 30653317]
    Huh-7 CC50
    > 10 μM
    Compound: 1; SOF
    Cytotoxicity against human HuH7 cells assessed as inhibition of cell proliferation after 4 days by MTS assay
    Cytotoxicity against human HuH7 cells assessed as inhibition of cell proliferation after 4 days by MTS assay
    		[PMID: 28595015]
    Huh-7 CC50
    > 10 μM
    Compound: Sofosbuvir
    Cytotoxicity against human HuH7 cells assessed as reduction in cell viability by MTT assay
    Cytotoxicity against human HuH7 cells assessed as reduction in cell viability by MTT assay
    		[PMID: 29066308]
    Huh-7 CC50
    > 100 μM
    Compound: SOF
    Cytotoxicity against human HuH7 cells assessed reduction in cell viability after 3 to 5 days by MTT assay
    Cytotoxicity against human HuH7 cells assessed reduction in cell viability after 3 to 5 days by MTT assay
    		[PMID: 30653317]
    Huh-7 CC50
    > 100 μM
    Compound: SOF; 1
    Cytotoxicity against human HuH7 cells assessed as reduction in rRNA levels after 5 days by RT-PCR analysis
    Cytotoxicity against human HuH7 cells assessed as reduction in rRNA levels after 5 days by RT-PCR analysis
    		[PMID: 30655167]
    Huh-7 CC50
    > 100 μM
    Compound: PSI-7977
    Cytotoxicity against human Huh7.5.1 cells after 48 hrs by luciferase reporter gene assay
    Cytotoxicity against human Huh7.5.1 cells after 48 hrs by luciferase reporter gene assay
    		[PMID: 27994763]
    Huh-7 CC50
    > 1000 μM
    Compound: 17
    Cytotoxicity against human HuH7 cells after 72 hrs by CellTiter 96 AQueous one solution cell proliferation assay
    Cytotoxicity against human HuH7 cells after 72 hrs by CellTiter 96 AQueous one solution cell proliferation assay
    		[PMID: 29172078]
    Huh-7 CC50
    > 20 μM
    Compound: Sofosbuvir
    Cytotoxicity against human HuH7 cells infected with HCV genotype 1b replicon after 72 hrs by CellTiter-Fluor reagent based fluorescence assay
    Cytotoxicity against human HuH7 cells infected with HCV genotype 1b replicon after 72 hrs by CellTiter-Fluor reagent based fluorescence assay
    		[PMID: 30683552]
    Huh-7 EC50
    0.053 μM
    Compound: 1
    Antiviral activity against HCV genotype 1b Con1 over expressing CES1 infected in human HuH7 replicon cells assessed as inhibition of viral replication after 3 days by luciferase reporter gene assay
    Antiviral activity against HCV genotype 1b Con1 over expressing CES1 infected in human HuH7 replicon cells assessed as inhibition of viral replication after 3 days by luciferase reporter gene assay
    		[PMID: 31740203]
    Huh-7 EC50
    0.062 μM
    Compound: 1
    Antiviral activity against HCV genotype 1b Con1 expressing wild type NS5B infected in human HuH7 replicon cells assessed as inhibition of viral replication after 4 days by luciferase reporter gene based assay
    Antiviral activity against HCV genotype 1b Con1 expressing wild type NS5B infected in human HuH7 replicon cells assessed as inhibition of viral replication after 4 days by luciferase reporter gene based assay
    		[PMID: 31740203]
    Huh-7 EC50
    0.0751 μM
    Compound: 1
    Antiviral activity against HCV genotype 3a expressing wild type NS5B infected in human HuH7 replicon cells assessed as inhibition of viral replication after 4 days by luciferase reporter gene based assay
    Antiviral activity against HCV genotype 3a expressing wild type NS5B infected in human HuH7 replicon cells assessed as inhibition of viral replication after 4 days by luciferase reporter gene based assay
    		[PMID: 31740203]
    Huh-7 EC50
    0.0785 μM
    Compound: 1
    Antiviral activity against HCV genotype 4a expressing wild type NS5B infected in human HuH7 replicon cells assessed as inhibition of viral replication after 4 days by luciferase reporter gene based assay
    Antiviral activity against HCV genotype 4a expressing wild type NS5B infected in human HuH7 replicon cells assessed as inhibition of viral replication after 4 days by luciferase reporter gene based assay
    		[PMID: 31740203]
    Huh-7 EC50
    0.0867 μM
    Compound: 1
    Antiviral activity against HCV genotype 6a expressing wild type NS5B infected in human HuH7 replicon cells assessed as inhibition of viral replication after 4 days by luciferase reporter gene based assay
    Antiviral activity against HCV genotype 6a expressing wild type NS5B infected in human HuH7 replicon cells assessed as inhibition of viral replication after 4 days by luciferase reporter gene based assay
    		[PMID: 31740203]
    Huh-7 EC50
    0.12 μM
    Compound: PSI-7977
    Antiviral activity against HCV JFH-1 infected in human HuH7.5.1 cells after 48 hrs by luciferase reporter gene assay
    Antiviral activity against HCV JFH-1 infected in human HuH7.5.1 cells after 48 hrs by luciferase reporter gene assay
    		[PMID: 27994763]
    Huh-7 EC50
    0.155 μM
    Compound: Sofosbuvir
    Inhibition of NS5B polymerase in HCV genotype 1a H77 infected in human HuH7 replicon cells assessed as inhibition of viral replication after 3 days by luciferase reporter gene assay
    Inhibition of NS5B polymerase in HCV genotype 1a H77 infected in human HuH7 replicon cells assessed as inhibition of viral replication after 3 days by luciferase reporter gene assay
    		[PMID: 32046903]
    Huh-7 EC50
    0.155 μM
    Compound: 1
    Antiviral activity against HCV genotype 1a H77 infected in human HuH7 replicon cells assessed as inhibition of viral replication after 3 days by luciferase reporter gene assay
    Antiviral activity against HCV genotype 1a H77 infected in human HuH7 replicon cells assessed as inhibition of viral replication after 3 days by luciferase reporter gene assay
    		[PMID: 31740203]
    Huh-7 EC50
    0.188 μM
    Compound: 1
    Antiviral activity against HCV genotype 1b Con1 infected in human HuH7 replicon cells assessed as inhibition of viral replication after 3 days by luciferase reporter gene assay
    Antiviral activity against HCV genotype 1b Con1 infected in human HuH7 replicon cells assessed as inhibition of viral replication after 3 days by luciferase reporter gene assay
    		[PMID: 31740203]
    Huh-7 EC50
    0.23 μM
    Compound: Sofosbuvir
    Inhibition of NS5B polymerase in HCV genotype 1b Con1 infected in human HuH7 replicon cells assessed as inhibition of viral replication after 3 days by luciferase reporter gene assay
    Inhibition of NS5B polymerase in HCV genotype 1b Con1 infected in human HuH7 replicon cells assessed as inhibition of viral replication after 3 days by luciferase reporter gene assay
    		[PMID: 32046903]
    Huh-7 EC50
    0.254 μM
    Compound: 25
    Antiviral activity against Hepatitis C virus genotype 1b in human Huh7-luc clone ET replicon cells assessed as inhibition of replicon replication after 3 days by luciferase assay
    Antiviral activity against Hepatitis C virus genotype 1b in human Huh7-luc clone ET replicon cells assessed as inhibition of replicon replication after 3 days by luciferase assay
    		[PMID: 24345201]
    Huh-7 EC50
    0.3301 μM
    Compound: 1
    Antiviral activity against HCV genotype 3a expressing NS5B S282T mutant infected in human HuH7 replicon cells assessed as inhibition of viral replication after 4 days by luciferase reporter gene based assay
    Antiviral activity against HCV genotype 3a expressing NS5B S282T mutant infected in human HuH7 replicon cells assessed as inhibition of viral replication after 4 days by luciferase reporter gene based assay
    		[PMID: 31740203]
    Huh-7 EC50
    0.6376 μM
    Compound: 1
    Antiviral activity against HCV genotype 1b Con1 expressing NS5B S282T mutant infected in human HuH7 replicon cells assessed as inhibition of viral replication after 4 days by luciferase reporter gene based assay
    Antiviral activity against HCV genotype 1b Con1 expressing NS5B S282T mutant infected in human HuH7 replicon cells assessed as inhibition of viral replication after 4 days by luciferase reporter gene based assay
    		[PMID: 31740203]
    Huh-7 EC50
    0.6813 μM
    Compound: 1
    Antiviral activity against HCV genotype 2a expressing wild type NS5B infected in human HuH7 replicon cells assessed as inhibition of viral replication after 4 days by luciferase reporter gene based assay
    Antiviral activity against HCV genotype 2a expressing wild type NS5B infected in human HuH7 replicon cells assessed as inhibition of viral replication after 4 days by luciferase reporter gene based assay
    		[PMID: 31740203]
    Huh-7 EC50
    1.002 μM
    Compound: 1
    Antiviral activity against HCV genotype 2a expressing NS5B S282T mutant infected in human HuH7 replicon cells assessed as inhibition of viral replication after 4 days by luciferase reporter gene based assay
    Antiviral activity against HCV genotype 2a expressing NS5B S282T mutant infected in human HuH7 replicon cells assessed as inhibition of viral replication after 4 days by luciferase reporter gene based assay
    		[PMID: 31740203]
    Huh-7 CC50
    200 μM
    Compound: Sofosbuvir
    Cytotoxicity against human HuH7 cells assessed as reduction in cell viability by measuring ATP level measured after 72 hrs by CellTiter-Glo luminescent assay
    Cytotoxicity against human HuH7 cells assessed as reduction in cell viability by measuring ATP level measured after 72 hrs by CellTiter-Glo luminescent assay
    		[PMID: 32435411]
    Huh-7 CC50
    200 μM
    Compound: Sofosbuvir
    Cytotoxicity against human Huh-7 cells assessed as reduction in cell viability by Celltiter-Glo luminescent cell viability assay
    Cytotoxicity against human Huh-7 cells assessed as reduction in cell viability by Celltiter-Glo luminescent cell viability assay
    		[PMID: 34273661]
    Huh-7 IC50
    3.8 μM
    Compound: Sofosbuvir
    Antiviral activity against Dengue virus serotype 2 New Guinea C infected at 50 TCID50 in human HuH7 cells assessed as inhibition of viral replication and 72 hrs later re-infected pre-seeded HuH7 cells with viral supernatant collected from previous infecte
    Antiviral activity against Dengue virus serotype 2 New Guinea C infected at 50 TCID50 in human HuH7 cells assessed as inhibition of viral replication and 72 hrs later re-infected pre-seeded HuH7 cells with viral supernatant collected from previous infecte
    		[PMID: 32435411]
    Huh-7.5 CC50
    > 200 μM
    Compound: SOF
    Cytotoxicity against human Huh7.5 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay
    Cytotoxicity against human Huh7.5 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay
    		[PMID: 35050619]
    Huh-7.5 CC50
    121.47 μM
    Compound: SOF
    Cytotoxicity against human Huh7.5 cells carrying HCV subgenomic replicons assessed as reduction in cell viability incubated for 96 hrs by MTT assay
    Cytotoxicity against human Huh7.5 cells carrying HCV subgenomic replicons assessed as reduction in cell viability incubated for 96 hrs by MTT assay
    		[PMID: 35050619]
    Huh-7.5 CC50
    170.85 μM
    Compound: SOF
    Cytotoxicity against human Huh7.5 cells infected with HCVcc assessed as reduction in cell viability incubated for 96 hrs by MTT assay
    Cytotoxicity against human Huh7.5 cells infected with HCVcc assessed as reduction in cell viability incubated for 96 hrs by MTT assay
    		[PMID: 35050619]
    PBMC CC50
    > 100 μM
    Compound: SOF
    Cytotoxicity against human PBMC assessed reduction in cell viability after 5 days by MTT assay
    Cytotoxicity against human PBMC assessed reduction in cell viability after 5 days by MTT assay
    		[PMID: 30653317]
    PBMC CC50
    > 100 μM
    Compound: 1; SOF
    Cytotoxicity against human PBMC assessed as inhibition of cell proliferation after 5 days by MTT assay
    Cytotoxicity against human PBMC assessed as inhibition of cell proliferation after 5 days by MTT assay
    		[PMID: 28595015]
    PBMC CC50
    > 100 μM
    Compound: Sofosbuvir
    Cytotoxicity against human PBMC assessed as reduction in cell viability after 6 days by trypan blue exclusion assay
    Cytotoxicity against human PBMC assessed as reduction in cell viability after 6 days by trypan blue exclusion assay
    		[PMID: 29066308]
    PBMC CC50
    > 100 μM
    Compound: SOF; 1
    Cytotoxicity against human PBMC after 6 days by trypan blue exclusion method
    Cytotoxicity against human PBMC after 6 days by trypan blue exclusion method
    		[PMID: 30655167]
    Vero CC50
    > 100 μM
    Compound: SOF
    Cytotoxicity against African green monkey Vero cells assessed reduction in cell viability after 3 days by MTT assay
    Cytotoxicity against African green monkey Vero cells assessed reduction in cell viability after 3 days by MTT assay
    		[PMID: 30653317]
    Vero CC50
    > 100 μM
    Compound: 1; SOF
    Cytotoxicity against African green monkey Vero cells assessed as inhibition of cell proliferation after 3 days by MTT assay
    Cytotoxicity against African green monkey Vero cells assessed as inhibition of cell proliferation after 3 days by MTT assay
    		[PMID: 28595015]
    Vero CC50
    > 100 μM
    Compound: Sofosbuvir
    Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 6 days by trypan blue exclusion assay
    Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 6 days by trypan blue exclusion assay
    		[PMID: 29066308]
    Vero CC50
    > 100 μM
    Compound: SOF; 1
    Cytotoxicity against African green monkey Vero cells after 3 days by hemocytometric method
    Cytotoxicity against African green monkey Vero cells after 3 days by hemocytometric method
    		[PMID: 30655167]
    Vero EC50
    30.9 μM
    Compound: 5
    Inhibition of RNA-dependent RNA polymerase in Zika virus infected in African green monkey Vero cells assessed as antiviral activity by DAPI-staining based assay
    Inhibition of RNA-dependent RNA polymerase in Zika virus infected in African green monkey Vero cells assessed as antiviral activity by DAPI-staining based assay
    		[PMID: 31549836]
    體外研究
    (In Vitro)

    When cathepsin A (CatA) is incubated with PSI-7977 or Sofosbuvir (PSI-7977) for 150 min, ~18-fold more PSI-352707 is formed when Sofosbuvir (PSI-7977) is the substrate compared with PSI-7976. Moreover, the catalytic efficiency for Sofosbuvir (PSI-7977) with CatA is ~30-fold higher than that for PSI-7976[1]. The genotype coverage of Sofosbuvir (PSI-7977) by using GT 1b (Con1)-, 1a (H77)-, and 2a (JFH-1)-derived replicons and GT 1b chimeric replicons containing the NS5B region from the J6 GT 2a isolate and from GT 2b and GT 3a patient isolates is evaluated, Sofosbuvir (PSI-7977) inhibits the replication of these replicons with similar EC50s (between 16 and 48 nM), and is especially active against the chimeric replicon containing the J6 NS5B (EC50=4.7 nM). Sofosbuvir (PSI-7977) inhibits clone A (GT 1b) wild-type and S282T replicons with EC90 values of 0.42 and 7.8 μM, respectively[2]. In the clone A replicon assay, Sofosbuvir (PSI-7977) produces anti-HCV activity with EC90 values 0.42 μM[3].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.
    Clinical Trial
    分子量

    529.45

    Formula

    C22H29FN3O9P
    CAS 號
    性狀

    固體

    顏色

    White to off-white

    中文名稱

    索非布韋；索氟布韋
    運(yùn)輸條件

    Room temperature in continental US; may vary elsewhere.
    儲存方式
    Powder -20°C 3 years
    4°C 2 years
    In solvent -80°C 2 years
    -20°C 1 year
    溶解性數(shù)據(jù)
    細(xì)胞實(shí)驗(yàn)： 

    DMSO 中的溶解度 : 50 mg/mL (94.44 mM; 超聲助溶; 吸濕的 DMSO 對產(chǎn)品的溶解度有顯著影響，請使用新開封的 DMSO)

    H2O 中的溶解度 : 25 mg/mL (47.22 mM; 超聲助溶 (<50°C))

    配制儲備液
    濃度 溶劑體積 質(zhì)量 1 mg 5 mg 10 mg
    1 mM 1.8888 mL 9.4438 mL 18.8875 mL
    5 mM 0.3778 mL 1.8888 mL 3.7775 mL
    查看完整儲備液配制表

    * 請根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲備液；一旦配成溶液，請分裝保存，避免反復(fù)凍融造成的產(chǎn)品失效。
    儲備液的保存方式和期限：-80°C, 2 years; -20°C, 1 year。-80°C儲存時(shí)，請?jiān)?年內(nèi)使用， -20°C儲存時(shí)，請?jiān)?年內(nèi)使用。

    * 備注：如您選擇水作為儲備液，請稀釋至工作液后，再用 0.22 μm 的濾膜過濾除菌后使用。

    • 摩爾計(jì)算器

    • 稀釋計(jì)算器

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    質(zhì)量
    =
    濃度
    ×
    體積
    ×
    分子量 *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    濃度 (start)

    C1

    ×
    體積 (start)

    V1

    =
    濃度 (final)

    C2

    ×
    體積 (final)

    V2

    動(dòng)物實(shí)驗(yàn)：

    請根據(jù)您的 實(shí)驗(yàn)動(dòng)物和給藥方式 選擇適當(dāng)?shù)娜芙夥桨浮?

    以下溶解方案都請先按照 In Vitro 方式配制澄清的儲備液，再依次添加助溶劑：
    ——為保證實(shí)驗(yàn)結(jié)果的可靠性，澄清的儲備液可以根據(jù)儲存條件，適當(dāng)保存；體內(nèi)實(shí)驗(yàn)的工作液，建議您現(xiàn)用現(xiàn)配，當(dāng)天使用；
    以下溶劑前顯示的百分比是指該溶劑在您配制終溶液中的體積占比；如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過加熱和/或超聲的方式助溶

    • 方案 一

      請依序添加每種溶劑： 10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 1.67 mg/mL (3.15 mM); 澄清溶液

      此方案可獲得 ≥ 1.67 mg/mL（飽和度未知）的澄清溶液。

      以 1 mL 工作液為例，取 100 μL 16.7 mg/mL 的澄清 DMSO 儲備液加到 400 μL PEG300 中，混合均勻；再向上述體系中加入 50 μL Tween-80，混合均勻；然后再繼續(xù)加入 450 μL 生理鹽水 定容至 1 mL。

      生理鹽水的配制：將 0.9 g 氯化鈉，溶解于 ddH?O 并定容至 100 mL，可以得到澄清透明的生理鹽水溶液。
    • 方案 二

      請依序添加每種溶劑： 10% DMSO    90% (20% SBE-β-CD in Saline)

      Solubility: ≥ 1.67 mg/mL (3.15 mM); 澄清溶液

      此方案可獲得 ≥ 1.67 mg/mL（飽和度未知）的澄清溶液。

      以 1 mL 工作液為例，取 100 μL 16.7 mg/mL 的澄清 DMSO 儲備液加到 900 μL 20% 的 SBE-β-CD 生理鹽水水溶液 中，混合均勻。

      2 g SBE-β-CD（磺丁基醚 β-環(huán)糊精）粉末定容于 10 mL 的生理鹽水中，完全溶解至澄清透明。

    以下溶解方案，請直接配制工作液。建議現(xiàn)用現(xiàn)配，在短期內(nèi)盡快用完。 以下溶劑前顯示的百分比是指該溶劑在您配制終溶液中的體積占比； 如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過加熱和/或超聲的方式助溶。

    • 方案 一

      請依序添加每種溶劑： PBS

      Solubility: 4.55 mg/mL (8.59 mM); 澄清溶液; 超聲助溶

    動(dòng)物溶解方案計(jì)算器
    請輸入動(dòng)物實(shí)驗(yàn)的基本信息：

    給藥劑量

    mg/kg

    動(dòng)物的平均體重

    g

    每只動(dòng)物的給藥體積

    μL

    動(dòng)物數(shù)量

    只
    由于實(shí)驗(yàn)過程有損耗，建議您多配一只動(dòng)物的量
    計(jì)算結(jié)果
    工作液所需濃度 : mg/mL
    該產(chǎn)品水溶性佳，請具體參考實(shí)測 水 / PBS / Saline 中的溶解度數(shù)據(jù)。
    您所需的儲備液濃度超過該產(chǎn)品的實(shí)測溶解度，如有需要，請與 MCE 中國技術(shù)支持聯(lián)系。
    純度 & 產(chǎn)品資料

    純度: 99.97%

    參考文獻(xiàn)
    Cell Assay
    [1]

    Clone A cells are seeded into T75 flasks at about 5×106 cells/flask in Dulbecco's modified Eagle's medium (DMEM) containing 100 IU/mL Penicillin/100 μg/mL streptomycin and 10% fetal bovine serum. Similarly, human primary hepatocytes are seeded in cell plating medium into T75 flasks at about 5×106 cells/flask. After overnight incubation to allow the cells to attach, cells are incubated with 50 μM PSI-7851, PSI-7976, or Sofosbuvir (PSI-7977) in fresh medium for clone A cells or in cell maintenance medium for primary hepatocytes for up to 24 h at 37°C in a 5% CO2 atmosphere. The same procedures are applied when radiolabeled PSI-7851 is used in the study except that 1×106 cells per well are seeded into a 6-well plate, and the cells are incubated with 5 μM [3H]PSI-7851. At selected times, the medium is removed, and the cell layer is washed with cold phosphate-buffered saline (PBS). After trypsinization, cells are counted and centrifuged at 1,200 rpm for 5 min. The cell pellets are suspended in 1 mL of cold 60% methanol and incubated overnight at ?20°C. The samples are centrifuged at 14,000 rpm for 5 min, and the supernatants are collected and dried using a SpeedVac concentrator and stored at ?20°C until they are analyzed by high performance liquid chromatography (HPLC). Residues are suspended in 100 μL of water, and 50-μL aliquots are injected into HPLC[1].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.
    參考文獻(xiàn)

    Sofosbuvir 相關(guān)分類

    完整儲備液配制表

    * 請根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲備液；一旦配成溶液，請分裝保存，避免反復(fù)凍融造成的產(chǎn)品失效。
    儲備液的保存方式和期限：-80°C, 2 years; -20°C, 1 year。-80°C儲存時(shí)，請?jiān)?年內(nèi)使用， -20°C儲存時(shí)，請?jiān)?年內(nèi)使用。

    可選溶劑 濃度 溶劑體積 質(zhì)量 1 mg 5 mg 10 mg 25 mg
    H2O / DMSO 1 mM 1.8888 mL 9.4438 mL 18.8875 mL 47.2188 mL
    5 mM 0.3778 mL 1.8888 mL 3.7775 mL 9.4438 mL
    10 mM 0.1889 mL 0.9444 mL 1.8888 mL 4.7219 mL
    15 mM 0.1259 mL 0.6296 mL 1.2592 mL 3.1479 mL
    20 mM 0.0944 mL 0.4722 mL 0.9444 mL 2.3609 mL
    25 mM 0.0756 mL 0.3778 mL 0.7555 mL 1.8888 mL
    30 mM 0.0630 mL 0.3148 mL 0.6296 mL 1.5740 mL
    40 mM 0.0472 mL 0.2361 mL 0.4722 mL 1.1805 mL
    DMSO 50 mM 0.0378 mL 0.1889 mL 0.3778 mL 0.9444 mL
    60 mM 0.0315 mL 0.1574 mL 0.3148 mL 0.7870 mL
    80 mM 0.0236 mL 0.1180 mL 0.2361 mL 0.5902 mL

    * 備注：如您選擇水作為儲備液，請稀釋至工作液后，再用 0.22 μm 的濾膜過濾除菌后使用。

    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    您最近查看的產(chǎn)品:

    Your information is safe with us. * Required Fields.

       產(chǎn)品名稱：

    		  

    * 需求量：

    * 客戶姓名：

    		 

    * Email：

    * 電話：

    		 

    * 公司或機(jī)構(gòu)名稱：

       留言給我們：

    Bulk Inquiry

    Inquiry Information

    產(chǎn)品名稱：
    Sofosbuvir
    目錄號：
    HY-15005
    需求量：